Doyle Mittie
Doyle Mittie, CMO, reported a transaction classified as exercise at Avalo Therapeutics, Inc. involving 679.000000 shares for an estimated $0.00. Reported holdings after the transaction were 113734.000000 shares. The stored filing text includes a detected 10b5-1 reference.
- Trade date
- Aug 28, 2026
- Filing date
- Sep 01, 2026
How reported position traded is calculated
Not calculated for derivative securities.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
AVTX price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- exercise Code M
- Identifier
- 0001918845-26-000031 Stock Option (Right to Buy)
- Transaction date
- Aug 28, 2026 Filed Sep 01, 2026, 08:38 PM · 4d delay
- Shares
- 679 sh $0.00 per share
- Estimated value
- $0 Computed from shares × price
- Holdings after
- 113,734 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
-20 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a meaningfully negative filing-only score. It is likely less useful as a positive insider-activity signal.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - derivative_transaction-16 points
is_derivative = true
Derivative exercise rows are less discretionary than open-market purchases. - tenb5_1_detected-10 points
is_10b5_1 = true
Stored filing content includes detected 10b5-1 language.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Chief Medical Officer
- F1
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
- F2
The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's con…
0 other transactions
0 recent txs